LAG3 and melanoma: Subsequently, anti-PD-1 antibodies were introduced in 2015, as well as the combination of BRAF inhibitors with MEK inhibitors and ipilimumab-nivolumab, both in 2016.4, 5, 6, 7 The treatment of advanced melanoma is still evolving with the introduction of new therapies, such as the lymphocyte-activation gene 3 (LAG-3) antibody and Tumor-Infiltrating Lymphocyte (TIL) therapy.8